Zydus Healthcare appoints Swati Dalal MD

 16 Jun 2025 03:06 PM

Zydus Lifesciences Ltd. has appointed Swati Dalal as an additional director and Managing Director of its subsidiary, Zydus Healthcare Ltd., effective June 16, 2025, for a five-year term. Dalal brings over 30 years of experience, most recently serving as Managing Director of Abbott India Ltd. Her career includes leadership roles at Wockhardt Nutrition, Boots, Knoll, Solvay, and Abbott.

Zydus Lifesciences gets USFDA nod for generic cholesterol lowering drug

 30 Apr 2025 11:49 AM

Zydus Lifesciences Ltd. has secured final USFDA approval to manufacture generic Niacin extended-release tablets in 500 mg, 750 mg, and 1,000 mg strengths. These tablets, produced in Ahmedabad, address elevated cholesterol and triglycerides, reducing the risk of myocardial infarction. The US market for these tablets has annual sales of USD 5.5 million, according to IQVIA MAT February 2025 data.

Zydus Lifesciences gets USFDA nod to produce prostate cancer treatment drug

 18 Mar 2025 07:03 PM

Zydus Lifesciences Ltd has received final approval from the USFDA to manufacture 60 mg Apalutamide tablets for prostate cancer treatment. These tablets will be produced at their Ahmedabad facility. Apalutamide, an androgen receptor inhibitor, is intended for metastatic castration-sensitive prostate cancer and had annual sales of USD 1,099.8 million in the US.

Zydus Lifesciences joins hands with CVS Caremark for diabetes drugs template formulary

 07 Jan 2025 02:13 PM

Zydus Lifesciences Ltd enters an agreement with CVS Caremark to add Zituvio, Zituvimet, and Zituvimet XR tablets for diabetes treatment to CVS’s template formulary starting January 1, 2025. This collaboration validates Zydus' new drug applications portfolio and aims to improve access to high-quality medications for patients.

Zydus Lifesciences gets WHO prequalification for Typhoid Vi conjugate vaccine

 23 Oct 2024 11:30 AM

Zydus Lifesciences Ltd has received in-principle approval from the WHO for its Typhoid Vi conjugate vaccine, ZyVac TCV. Eligible for UN procurement, the vaccine targets 6-month to 65-year-olds and addresses high typhoid incidence in India, Africa, and Southeast Asia.

Zydus gets WHO nod for its typhoid vaccine

 23 Oct 2024 11:30 AM

Zydus Lifesciences Ltd has received in-principle approval from the WHO for its Typhoid Vi conjugate vaccine, ZyVac TCV. Eligible for UN procurement, the vaccine targets 6-month to 65-year-olds and addresses high typhoid incidence in India, Africa, and Southeast Asia.